Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib for Idiopathic Pulmonary Fibrosis – Phase II
CTR20200904Phase 2Completed
- Sponsor
- Suzhou Zelgen Biopharmaceuticals
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of jaktinib in idiopathic pulmonary fibrosis (IPF), sponsored by Suzhou Zelgen Biopharmaceuticals. Started Jul 2020; status: completed.
02
Drugs
jaktinib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20200904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200904.